{"filings":[{"id":816398,"accession_number":"0001683168-26-004481","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-06-03T13:00:15+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Valion Bio shareholders approve 2.58M share increase to 2021 equity plan; Dean Zikria re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved a 2,581,608 share increase under the 2021 Equity Incentive Plan (736,919 for, 134,918 against).","Dean Zikria was elected Class II director with 873,001 votes for and 59,543 withheld.","Ratification of Rosenberg Rich Baker Berman as auditor for FY 2026 passed with 1,510,322 votes for.","Proposals 4-7 (issuances to institutional investors and Tumim) approved with ~65-66% of votes cast in favor.","Adjournment proposal approved (1,328,670 for) but not needed as all other proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443717,"accession_number":"0001437749-26-017082","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-05-14T20:36:14+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).","Cash and equivalents $7.2M at March 31, 2026, down from $12.6M at Dec 31, 2025.","Government engagement broadened with BARDA, NIAID, and Dept of War for Entolimod as ARS countermeasure.","Velocity Bioworks CDMO integration advancing; facility supports internal and third-party biologics manufacturing.","Pipeline includes Entolimod (Animal Rule pathway) and Entolasta (TLR5 agonist for oncology supportive care)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95464,"accession_number":"0001683168-26-003446","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Valion Bio appoints Melinda Lackey as General Counsel and SVP of Legal Affairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melinda Lackey, age 49, appointed as GC and SVP of Legal Affairs, effective May 4, 2026.","Prior role: SVP Legal & Administration at Alaunos Therapeutics (TCRT); also served at Kuur Therapeutics and Winston & Strawn.","Employment agreement: base salary $321,000/year, eligible for annual bonus up to 35% of base, and option grant of 45,000 shares.","Lackey will oversee legal functions for Valion's Entolimod ARS program and CDMO subsidiary Velocity Bioworks.","Company (Nasdaq: VBIO) is a clinical-stage immunotherapeutics firm advancing Entolimod via FDA Animal Rule pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95463,"accession_number":"0001683168-26-003161","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tivic Health rebrands as Valion Bio; ticker to VBIO; targets BARDA SNS procurement for Entolimod","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corporate name changes to Valion Bio, Inc.; Nasdaq ticker to change from TIVC to VBIO effective April 28, 2026.","Lead asset Entolimod (TLR5 agonist) for Acute Radiation Syndrome has FDA Fast Track, Orphan Drug, and Animal Rule designations.","Engaged with BARDA, DTRA, NIAID for Strategic National Stockpile procurement; potential nine-figure non-dilutive revenue event.","Parallel oncology indication: chemotherapy-induced neutropenia; targeting Phase IIb readiness; market over $22B.","Velocity Bioworks CDMO subsidiary (acquired ~$16.3M) completed 200-fold scale-up; offers independent third-party revenue stream."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108564,"accession_number":"0001437749-26-009789","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tivic reports FY2025 net loss $8.8M-$9.1M; pivots to immunotherapy with Entolimod","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses $7.9M in 2025 vs $4.5M in 2024; net loss before disc. ops $7.9M-$8.1M.","Cash $12.6M at Dec 31, 2025 vs $2.0M at prior year-end; working capital $12.4M.","Acquired global rights to Entolimod for acute radiation syndrome; discontinued ClearUP/VNS.","CEO Michael K. Handley appointed March 2026, succeeding Jennifer Ernst.","Engaged with BARDA, DTRA, NIH, NIAID for potential Entolimod funding or procurement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108563,"accession_number":"0001683168-26-002064","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tivic Health receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notification on March 19, 2026 for bid price below $1.00 for 30 consecutive business days.","Compliance period ends September 15, 2026; must have closing bid ≥$1.00 for 10 consecutive days.","If not compliant by Sept 15, may qualify for second 180-day period if other listing standards met.","Stock remains listed on Nasdaq Capital Market with no immediate effect on trading.","Company will monitor and consider available options to resolve the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108562,"accession_number":"0001683168-26-001781","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tivic Health subsidiary Velocity Bioworks signs three facility leases totalling ~$11.6M base rent","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Microbial Building Lease: 8,024 sq ft, 8-year term, $5.34M aggregate base rent; option to purchase for $12.5M within first 24 months.","Mammalian Building Lease: 20,144 sq ft, 102-month term, $6.29M aggregate base rent; monthly rent $55,030 with 3% annual escalations.","Office Sublease: 8,122 sq ft, 110-month term; monthly base rent starts at $31,045 with 3% annual increases.","All leases are at 1305 E. Houston St., San Antonio, TX; office sublease will become new principal executive office.","Security deposit for Microbial Building: $350,000 letter of credit; VBI also pays share of operating expenses and taxes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108561,"accession_number":"0001683168-26-001687","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Tivic Health cancels special stockholder meeting after failing to achieve quorum; withdraws proposals","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Special meeting held Feb 19, 2026 adjourned due to lack of quorum; less than one-third of shares present.","Record date Dec 29, 2025: 2,525,778 shares outstanding entitled to vote.","Adjourned meeting scheduled for Mar 12, 2026 was canceled by board on Mar 11, 2026.","Board withdrew all proposals set forth in the proxy statement filed Jan 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108560,"accession_number":"0001683168-26-001461","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tivic Health CEO Jennifer Ernst resigns; Michael Handley appointed CEO to lead biopharma pivot","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jennifer Ernst resigned March 2, 2026; board departure effective March 5; separation includes $325K cash severance, COBRA, equity vesting, and $50K restricted stock.","Michael Handley appointed CEO and board member effective March 3; previously COO and President of Tivic Biopharma since February 2025.","Handley brings over 20 years life sciences experience; led commercialization of 17 products, worked at Amgen and Genentech.","Company shifts strategic focus to late-stage immunotherapies and biomanufacturing subsidiary Velocity Bioworks; highlights Entolimod as key asset.","No dispute or disagreement with Ernst's resignation; Handley's existing employment agreement unchanged from February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108557,"accession_number":"0001683168-26-001263","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K/A","filed_at":"2026-02-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Tivic Health files Scorpius audited financials; FY2024 net loss $32.8M on $6.2M revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Scorpius FY2024 revenue $6.24M, net loss $32.8M; auditor BDO flags going-concern doubt due to recurring losses.","Scorpius total assets $39.2M, total liabilities $37.5M, stockholders' equity $1.7M at Dec 31, 2024.","Tivic sub Velocity Bioworks acquired all Scorpius assets on Dec 9, 2025, assuming no pre-closing liabilities.","Pro forma combined financials filed for Sep 30, 2025 and FY2024; combined company impact not quantified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108559,"accession_number":"0001683168-26-000877","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tivic Health enters $50M equity line with Tumim Stone Capital; pre-funded warrant issued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common Stock Purchase Agreement allows Tivic to sell up to $50M of common stock to Tumim Stone Capital at 97% or 95% of VWAP.","Pre-funded warrant for 437,012 shares at $0.0001 per share issued as commitment fee; warrants exercisable immediately.","Exchange Cap set at 506,848 shares (19.99% of outstanding) unless average sale price equals or exceeds $1.02 per share.","Daily maximum draw is $1M (one-day valuation) or $2.5M (three-day valuation) with volume limits of 15% or 40% of daily volume.","Registration Rights Agreement filed to register resale of shares issued under the Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108558,"accession_number":"0001683168-26-000398","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tivic Health releases corporate presentation highlighting late-stage pipeline in radiation damage and oncology","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company targeting multiple high-value inflection points expected within the next 18-24 months.","Focus on competitively differentiated treatments for radiation damage, oncology, and immune system modification.","Pipeline described as late-stage and highly de-risked; experienced management team in place.","Corporate presentation furnished as Exhibit 99.1; no specific financial or clinical data disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125003,"accession_number":"0001683168-25-009079","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","5.03","1.02","2.01","2.03","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Tivic Health acquires Scorpius CDMO assets and closes $16.25M note and $12M preferred offerings","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Scorpius CDMO assets for $16.25M cash via Article 9 sale through subsidiary Velocity Bioworks.","Issued $16.25M senior secured convertible note to 3i, with 5% interest and 5-year maturity, to fund the acquisition.","Sold 12,000 Series C preferred shares at $1,000 each for $12M in initial tranche; potential total up to $75M.","Terminated $25M equity purchase agreement with Mast Hill Fund on December 9, 2025.","Amended April 2025 purchase agreement with 3i to extend termination and lower floor price to $0.39."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125002,"accession_number":"0001437749-25-035521","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Tivic Health secures BARDA Techwatch meeting for Entolimod ARS program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program staff to discuss Entolimod for acute radiation syndrome.","Tivic will present clinical data, manufacturing readiness, and BLA preparations; meeting may lead to funding or purchasing.","Entolimod has FDA Fast Track and Orphan Drug designations for ARS.","CEO states this supports strategy for government partnership or acquisition pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125001,"accession_number":"0001437749-25-035208","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","7.01","2.05","9.01"],"status":"ready","headline":"Tivic Health winds down ClearUP consumer biz; Q3 net loss $2.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $146K (+16% YoY); gross loss $145K from $230K inventory reserve for ClearUP exit.","Net loss $2.6M vs $1.4M in Q3 2024; operating expenses rose to $2.3M on biopharma costs.","ClearUP wind down: $347K charge incurred, $20-50K more expected; minimal revenue until approval.","Transferred two INDs for Entolimod (neutropenia, cancer); cell line verification for cGMP completed.","Cash $3.5M; $3.5M available via preferred equity; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":302000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125000,"accession_number":"0001683168-25-008287","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health study: personalized ncVNS boosts HRV 46%, 8.9x vs fixed frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Personalizing stimulation frequency increased heart rate variability by 46%, 8.9x more effective than uniform frequency across subjects.","Optimal frequency varied between visits for each subject, highlighting need for pre-treatment personalization.","Electrode placement significantly impacted HRV; some configurations reduced HRV markedly while others increased it.","Four minutes of ncVNS stimulation drove large HRV increase and was more effective than twenty minutes.","CEO sees potential clinical utility in ischemic stroke, PTSD, and inflammatory diseases; plans in-house or partnered development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124999,"accession_number":"0001437749-25-031054","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tivic Health enters new CEO employment agreement with Jennifer Ernst; base salary $325K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jennifer Ernst, CEO, enters new employment agreement effective Oct 8, 2025, replacing prior offer letter.","Base salary of $325,000 per annum; eligible for annual bonus up to 50% of base salary at Board discretion.","Severance: 12 months of base salary continuation, COBRA coverage, and continued equity vesting if terminated without cause or for good reason.","Severance conditioned on signing a release; no severance for voluntary quit (except good reason), cause, death, or disability.","Employment remains 'at will'; prior confidentiality and arbitration agreements remain in force."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141697,"accession_number":"0000950170-25-111709","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tivic Health appoints Odyssey Transfer as new transfer agent and warrant agent effective Aug 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective August 30, 2025, Odyssey Transfer and Trust replaces Equiniti as transfer agent and registrar.","Odyssey will also succeed Equiniti as warrant agent for the Series B Warrants issued on May 13, 2024.","All registered share records will be transferred from Equiniti to Odyssey on or before the effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141696,"accession_number":"0000950170-25-110374","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health receives two INDs for Entolimod from Statera for ARS and advanced cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed transfer of two INDs from Statera Biopharma for lead candidate Entolimod.","INDs cover acute radiation syndrome (ARS-H and ARS-GI sub-syndromes) and advanced cancers.","Enables formal FDA engagement on regulatory pathway for ARS; near-term focus on ARS as first indication.","Also enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-treatment conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141695,"accession_number":"0000950170-25-108835","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tivic Health Q2 revenue down 39% to $86k; net loss widens to $1.9M; plans to exit ClearUP, focus on biopharma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $86k (-39% YoY); net loss $1.9M vs $1.3M in Q2 2024; cash $1.2M at June 30.","Raised $0.9M post-quarter; $7M committed via preferred equity; no debt on balance sheet.","Plans to exit ClearUP consumer healthtech by year-end; shifts resources to TLR5 agonist Entolimod.","Extended Entolimod license to include neutropenia; completed study visits for ncVNS device.","Named Lisa Wolf as permanent CFO; expanded biopharma team with regulatory and clinical staff."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":156000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141693,"accession_number":"0000950170-25-098773","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K/A","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tivic Health amends license deal with Statera; royalties payable in stock; lien up to $5.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalties may be paid in cash or Tivic securities at Tivic's discretion under the A&R License Agreement.","Avenue Venture Opportunities Fund lien increased to up to $5.6 million (Payoff Amount).","After initial fees and first milestone, 80% of subsequent payments go directly to Avenue until lien satisfied.","Initial license fee already paid: $300K cash plus 945,785 common shares and convertible preferred shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141694,"accession_number":"0000950170-25-094222","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tivic Health appoints permanent CFO; CSO Gurfein departs; stockholders OK 425K share equity plan increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Wolf appointed permanent CFO effective July 7, 2025; base salary $240,000 plus bonus up to 35% of base.","CSO Blake Gurfein stepped down July 4, 2025, to pursue other opportunities; will consult for at least 6 months at $20,000/month.","Gurfein receives lump sum severance of $45,938 upon signing release; no disagreement with company.","Stockholders approved amendment to 2021 Equity Plan to increase authorized shares by 425,000 (131,428 votes for).","Stockholders approved share issuances under Statera license, April 2025 SPA, and Mast Hill equity line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159594,"accession_number":"0000950170-25-089981","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tivic Health amends Statera license; may pay royalties in securities, directs up to $5.6M to Avenue Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended license agreement gives Tivic discretion to pay future royalties in cash or its own securities.","Subsequent payments to Statera, up to $5.6M aggregate, will be paid directly to Avenue Capital on Statera's behalf.","Original exclusive license for Entolimod (TLR5 agonist) for Acute Radiation Syndrome and option for other indications unchanged.","License fee of $300K cash plus 945,785 common shares and convertible preferred shares already paid at closing in Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159593,"accession_number":"0000950170-25-089741","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tivic Health completes Optimization Study for ncVNS device; results due later in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All study visits completed for patent-pending non-invasive cervical vagus nerve stimulation device.","Initial findings reinforce importance of personalization for therapeutic efficacy; detailed results expected later this year.","Earlier findings presented at Bioelectronic Medicine Summit on March 4, 2025.","CEO Jennifer Ernst says breakthroughs increase confidence in novel bioelectronic approach.","Global VNS market forecast at $21.3B by 2030; peripheral nerve stimulation segment growing at 35% CAGR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159592,"accession_number":"0000950170-25-076060","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tivic Health furnishes Sidoti conference presentation; exhibit content not fully provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Jennifer Ernst to present at Sidoti Micro Cap Conference on May 22, 2025.","Corporate presentation dated May 2025 is attached as Exhibit 99.1 but is incomplete in the filing.","The presentation is also available on the company's investor website.","No new financial or operational data beyond the presentation is disclosed; filing is procedural."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159591,"accession_number":"0000950170-25-075301","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Tivic Health sets 2025 Annual Meeting for June 30; updates shareholder proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting to be held virtually on June 30, 2025; record date May 14, 2025.","Rule 14a-8 stockholder proposals must be received by May 26, 2025.","Universal proxy rule notices for director nominations due by May 30, 2025.","Company reserves the right to change the meeting date and/or record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159590,"accession_number":"0000950170-25-072603","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tivic Health Q1 revenue drops 79% to $70K; pursues Entolimod and ncVNS pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 79% YoY to $70K; net loss unchanged at $1.5M. Cash $669K vs $2.0M at year-end.","Licensed Phase III TLR5 agonist Entolimod for ARS; began GMP manufacturing validation for BLA.","Briefed White House and FDA on defense applications; secured $25M equity line and $8.4M purchase agreement.","Expanded ncVNS optimization study; regained Nasdaq compliance via 1-for-17 reverse split in March.","Gross margin improved to 72% (vs 50% a year ago) but operating expenses flat at $1.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159589,"accession_number":"0000950170-25-070948","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Tivic Health enters $4.1M GMP manufacturing agreement with Scorpius for Entolimod ARS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scorpius BioManufacturing to perform GMP validation for Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS).","Total estimated investment ~$4.1M comprising ~$2.4M service fees and pass-through costs for consumables, external services.","Scorpius to perform cell line verification, GMP scale-up, fill/finish, analytical development, process optimization.","Purpose is to prepare complete CMC package for FDA BLA submission for Entolimod.","Manufacturing at Scorpius' San Antonio, TX facility; aims for leaner supply chain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159588,"accession_number":"0000950170-25-062733","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","9.01"],"status":"ready","headline":"Tivic Health enters up to $8.4M Series B Preferred financing with Helena Global","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $8.4M from sale of Series B Non-Voting Convertible Preferred at $1,000/share plus warrants for common stock.","Six tranche closings: initial $700k, then $700k, then $1.75M each for four more; warrants cover 30% of underlying common.","Series B Preferred: 10% cumulative annual dividend, convertible at 90% of 5-day VWAP (floor $1.294).","Registration rights: Company to file resale registration statement within 15 days for conversion and warrant shares.","Stockholder approval required for second tranche and beyond; Exchange Cap of 19.99% of outstanding common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159587,"accession_number":"0000950170-25-056480","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health briefed White House and FDA on TLR5 candidates and ncVNS; positive interest noted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On April 17, 2025, briefed White House senior leadership on Entolimod for acute radiation syndrome and need for advanced treatments.","Met with FDA to discuss expedited pathways for Entolimod, Entolasta (second-gen TLR5 agonist), and non-invasive cervical VNS technology.","Previous U.S. government funding from BARDA, NASA, DTRA, DoD, and Army for TLR5 program highlighted.","Positive interest in military/defense applications; FDA explored breakthrough device designations for ncVNS after clinical work.","CEO Jennifer Ernst expects continued discussions as programs progress toward potential FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159586,"accession_number":"0000950170-25-053769","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health adds $1.77M baby shelf capacity under existing Equity Distribution Agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company may sell up to $1,767,913 in common stock through Maxim Group under updated prospectus supplement.","Sales are under existing $10M Equity Distribution Agreement dated Sept 2024, subject to Form S-3 baby shelf limit.","Legal opinion of Snell & Wilmer L.L.P. regarding the shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159585,"accession_number":"0000950170-25-052679","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tivic Health regains Nasdaq minimum bid price compliance; stock continues listing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq confirmation on April 4, 2025 that minimum bid price compliance is regained.","Reverse stock split implemented on March 7, 2025 as required by Nasdaq Hearings Panel.","Company had been notified of deficiency in June 2024 and received extension through panel decision.","Common stock (TIVC) continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159584,"accession_number":"0000950170-25-050485","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Tivic Health exercises option for Neutropenia license; accelerates $500K milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised Exclusive Option on March 28, 2025 to license Neutropenia indication of Entolimod from Statera.","Accelerated first milestone payment of $500,000 for IND and Phase 2 study for Neutropenia.","Issued 55,704 common shares and 131.1267 Series A Preferred shares to Statera and Avenue as consideration.","Obligated to develop Neutropenia indication at own cost and pay future milestones up to $2.75M for this indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177968,"accession_number":"0000950170-25-043166","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["1.01","2.02","7.01","3.02","9.01"],"status":"ready","headline":"Tivic Health FY2024 net loss narrows to $5.7M; secures $25M equity line, in-licenses Entolimod","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $0.8M (down from $1.2M); net loss -$5.7M vs -$8.2M in 2023 (30% decrease).","Entered $25M equity purchase agreement with Mast Hill Fund; issued 29,800 commitment shares.","In-licensed late-stage TLR5 agonist Entolimod from Statera Biopharma for acute radiation syndrome (Phase III).","Appointed Michael Handley as COO and President of Tivic Biopharma; Lisa Wolf as interim CFO.","ncVNS optimization study completed enrollment; disease-specific trials planned in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177967,"accession_number":"0000950170-25-034191","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health presents data showing personalized VNS nearly doubles HRV in 60% of participants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data from Feinstein Institute collaboration presented at Sixth Bioelectronic Medicine Summit.","Personalized ncVNS frequency optimized HRV change; no single frequency universally dominant.","60% of participants (responders) saw raw HRV nearly double on average post-stimulation.","Normalized HRV increased 2.67x, indicating enhanced vagal tone and improved autonomic balance.","Company believes findings support non-invasive devices for inflammatory, cardiac, neurologic disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177966,"accession_number":"0000950170-25-033091","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Tivic Health announces 1-for-17 reverse stock split effective March 7, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:17 ratio; effective 12:01 a.m. ET on March 7, 2025.","Purpose: regain Nasdaq $1.00 minimum bid price after delisting notice received December 2024.","Hearing before Nasdaq Panel held Feb 18, 2025; company awaits decision but expects split to aid listing.","No fractional shares; any fractional interest rounded up to nearest whole share.","Trading symbol TIVC unchanged; new CUSIP 888705308."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177965,"accession_number":"0000950170-25-025238","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tivic Health names Michael Handley COO and President of Tivic Biopharma following Statera license","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Handley appointed COO and President of new Tivic Biopharma division, effective Feb 18, 2025.","Compensation: $300k base salary, up to 35% bonus, 600k RSUs vesting over 4 years.","Handley previously CEO of Statera Biopharma; helped commercialize 17 drugs/devices worth ~$7B in sales.","Role includes advancing late-stage Entolimod (TLR5 agonist) for radiation protection and immune indications.","Appointment follows Feb 11 exclusive license of Entolimod from Statera, previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177964,"accession_number":"0000950170-25-018419","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","5.03","3.02","7.01","9.01"],"status":"ready","headline":"Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.","Potential milestones up to $1.75M for ARS and $6.5M for additional indications, total $8.25M.","Exclusive option to expand license to five additional indications including Lymphocyte Exhaustion and Neutropenia.","Entolimod has FDA Fast Track & Orphan Drug designation; prior investment $140M; potential BLA filing within 24 months.","Statera gets Board seat nomination; Tivic to hold stockholder vote on Series A conversion within 120 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177963,"accession_number":"0000950170-25-014601","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tivic Health shareholders approve reverse stock split authorization (1:2 to 1:30)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio range authorized: 1-for-2 to 1-for-30, at board discretion within 12 months.","Proposal passed with 3,028,943 votes for, 243,254 against, 33,240 abstentions.","Quorum was 34.9% (3,305,437 of 9,467,327 outstanding shares).","Adjournment proposal also approved but not needed; meeting not adjourned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177962,"accession_number":"0000950170-25-001140","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tivic Health receives Nasdaq delisting notice; hearing requested, reverse split proposed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tivic on Dec 27, 2024 it failed to regain $1.00 bid price compliance and is ineligible for a second 180-day period due to equity deficiency.","Company requested a hearing on Jan 3, 2025, which automatically stays any suspension or delisting pending the hearing and Panel decision.","Special stockholder meeting set for Jan 31, 2025 to vote on reverse stock split (ratio 1:2 to 1:30) to regain bid price compliance.","No assurance that the company will regain compliance or that the Nasdaq Panel will grant continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194669,"accession_number":"0001683168-24-008948","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tivic Health reports >65% DTC gross margin, advances VNS program with Feinstein Institute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ClearUP 2.0 launched; McKesson & Cardinal Health partnerships accelerating; customer reviews 4.4 stars; defect returns down.","D2C gross margin over 65% (vs <28% in 2023); net operating loss reduced more than 30%.","VNS pilot study with Feinstein Institute showed best-in-industry results; second study fully enrolled, data expected next year.","Targeting $30B+ annual market opportunity in non-invasive VNS; 16 issued patents, 10 pending internationally.","Plans disease-specific clinical trials in 2025, working to regain Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194668,"accession_number":"0000950170-24-127045","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tivic Health Q3 revenue $126K, down 27% YoY; net loss narrows to $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for nine months ended Sep 30, 2024: $600K, down 27% vs 2023 on 36% fewer units sold.","Net loss in Q3 2024 was $1.4M vs $1.8M in Q3 2023; operating expenses cut $1.9M YTD.","Cash at Sep 30: $2.2M; raised $775K net in Oct-Nov via stock sales.","Completed Phase 1a optimization study for non-invasive VNS; partnered with Fletcher Spaght.","Appointed Lisa Wolf as interim CFO effective Oct 1; supply chain redesigned for higher margins."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":600000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210973,"accession_number":"0000950170-24-107614","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health receives IRB approval from Feinstein Institutes for ncVNS optimization study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received IRB approval from Feinstein Institutes for clinical optimization study of ncVNS; enrollment to commence.","Study will optimize stimulation parameters and electrode positioning using physiological measurements.","Data will guide selection of clinical populations and design of future disease-specific trials.","Collaboration with Fletcher Spaght to identify high-unmet-need clinical applications for ncVNS.","Global VNS market valued at $8.59B (2021), projected $21.3B by 2030, CAGR 10.6%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210972,"accession_number":"0000950170-24-107032","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tivic Health Partners with Fletcher Spaght to Accelerate ncVNS Commercial Strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnered with Fletcher Spaght, a healthcare growth strategy firm, to develop commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).","Fletcher Spaght identified ~30 potential use cases in neurologic, cardiac, psychiatric, and autonomic diseases.","Global VNS market projected to grow from $8.59B (2021) to $21.3B (2030) at 10.6% CAGR; peripheral nerve stimulation at 35% CAGR.","Tivic completed Phase 1 trial showing strong physiological effects in neurological, cardiac, and autonomic systems.","Company expects insights to drive clinical strategy and product development in 2025 and beyond."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210971,"accession_number":"0000950170-24-106464","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Tivic Health enters ATM equity facility up to $10M; appoints Lisa Wolf as interim CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity Distribution Agreement with Maxim Group for at-the-market sales of common stock up to $10M aggregate offering price; current baby shelf limit $1.44M.","Maxim receives 3.0% commission; Tivic reimburses up to $40K expenses plus $5K per bringdown.","Kimberly Bambach resigns as interim CFO effective Oct 1, 2024; remains advisor for strategic transactions.","Lisa Wolf appointed interim CFO effective Oct 1, 2024; paid $275/hour as non-employee consultant; has served Tivic since June 2022 via Murdock Martell.","Wolf brings 30 years experience, including CAO at Resonant (RESN) and CPA at Arthur Andersen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210970,"accession_number":"0000950170-24-097036","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tivic Health Q2 2024 revenue $140K, net loss $1.3M; Phase 1 VNS results, cost cuts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $140K vs $203K in Q2 2023; H1 2024 revenue $474K, down 12% YoY.","Net loss Q2 2024 $1.3M vs $2.1M; H1 net loss $2.7M, $1.5M improvement from H1 2023.","Gross margin improved to 42% in H1 2024 from 32% in H1 2023 due to cost reductions.","Cash and equivalents $3.7M as of June 30, 2024; raised $3.3M net from May 2024 offering.","Phase 1 VNS trial results with Feinstein Institutes; ClearUP 2.0 launched; lease and logistics savings."],"consensus_eps_estimate":-6.12,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":474000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210969,"accession_number":"0000950170-24-096305","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tivic Health stockholders approve 10x increase in equity plan shares to 1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["A&R Plan approved, increasing authorized shares from 92,376 to 1,000,000 (over 10x increase).","Two Class III directors elected: Jennifer Ernst (654,527 for) and Sheryle Bolton (596,810 for).","Rosenberg Rich Baker Berman ratified as independent auditor for FY2024 with 2,241,997 votes for.","Annual meeting quorum of approximately 38.7% (2,395,964 of 6,183,592 shares represented)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210968,"accession_number":"0000950170-24-089981","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Tivic Health terminates ALOM fulfillment agreement to reduce costs, transitions to in-house ops","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective August 1, 2024, terminated ALOM Fulfillment Services Agreement for convenience; no material early termination penalties.","Transitioned to alternate third-party logistics and in-house assembly/testing; no service disruption and capacity sufficient for foreseeable demand.","Minimum monthly purchase requirement of $25,000 was waived from January through June 2024 prior to termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210967,"accession_number":"0000950170-24-081608","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tivic Health receives Nasdaq delisting notice for bid price below $1.00 for 33 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on June 28, 2024 for non-compliance with minimum bid price requirement.","Closing bid price below $1.00 per share for 33 consecutive business days.","180-day cure period ends December 26, 2024; must close at or above $1.00 for 10 consecutive days.","If not compliant by deadline, may request a second 180-day period if other listing standards are met.","Listing remains fully effective during cure period; company evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229443,"accession_number":"0000950170-24-074605","cik":1787740,"company_name":"Valion Bio, Inc.","ticker":"VBIO","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.08","7.01","9.01"],"status":"ready","headline":"Tivic Health appoints Christina Valauri to board; Karen Drexler resigns effective Sep 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christina Valauri appointed director effective July 1, 2024; will chair Nominations & Corp Gov Committee.","Valauri brings 30+ years capital markets experience; served as advisor since April 2023.","Karen Drexler resigns as director effective Sep 30, 2024; will remain as strategic advisor.","2024 annual meeting set for Aug 9; record date June 17; shareholder proposals due June 27."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2600000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-18T23:59:59+00:00|229443"}